was measured in a variety of ways patients were deemed to have a complete clinical response cr if no tumours were evident following treatment tumours whose volume decreased by greater than 50 were deemed to have a partial response pr to therapy patients with tumours that exhibited no change in size were classified as having stable disease sd while patients with new tumours or whose tumours increased in size were said to have progressive disease pd patients who had a complete resolution of disease microscopically were deemed to have exhibited a complete pathologic response pcr using the above definitions of patient response to chemotherapy the relationship between average or maximum tumour rna values and clinical response to therapy was analyzed both average and maximum rin values were computed since one or both may have the greatest correlated with clinical response in the ma 22 patients 13 patients were observed to have crs while 37 patients were deemed nonresponders pr sd or pd only 7 of the 50 patients exhibited a pcr in particular a low average tumour rin post treatment was significantly associated with a cr p 0 01 while a low maximum rin was associated with a pcr mid treatment p 0 01 but not post treatment p 0 28 fig6 depicts the maximum tumour rin value for each patient pre mid and post treatment time patients that exhibited a pcr after epiribucin docetaxel chemotherapy are shown with dashed lines all patients that had a pcr post chemotherapy exhibited a reduction in maximum tumour rin mid treatment moreover both pcrs and reductions in tumour rins were observed preferentially in patients exposed to high drug dose levels levels 5 or higher it was noted that while a strong reduction in the maximum tumour rin was observed mid treatment for.